Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid TumorMetastatic Solid TumorNon Small Cell Lung CancerColorectal CancerKRAS G12CPancreatic Cancer
- Interventions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Frontier Medicines Corporation
- Target Recruit Count
- 403
- Registration Number
- NCT06244771
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center, Orange, California, United States
News
No news found